Skip to main content
  • Home
  • P2Y12 Receptor Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: An Assessment of Current Evidence

P2Y12 Receptor Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: An Assessment of Current Evidence

Topic:
  • MI/ACS

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Overview

The European Heart Association’s guideline update on NSTE-ACS management in 2020 took into consideration several landmark trials, which ultimately changed the level of recommendation on key aspects of antiplatelet use, in both pre- and post-PCI practice. This roundtable, led by Prof Dominick Angiolillo, considers the main updates, the data underpinning the changes and what they mean for real-world practice through expert discourse and case examination.

Terms & Conditions

In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

 

Intended for healthcare professionals only. This IME programme is supported by an unrestricted educational grant from AstraZeneca, who has had no involvement in its organisation. Views and opinions expressed in the programme belong to the authors (faculty and delegates) and not necessarily to that of AstraZeneca.

 

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

Instructions to Participants

There is no fee for taking part in this online learning activity.

 

Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Target Audience

This programme is intended to educate:

  • Heart Failure Specialists
  • General Cardiologists
  • Nurses
  • Allied Health Professionals

Learning Objectives

  • Recall the supportive evidence underpinning recommended antiplatelet approaches in individuals with unknown coronary anatomy, including choice of therapy, duration, timing and loading doses
  • Compare the design of different clinical trials that have influenced antiplatelet therapy choice in NSTE-ACS patients who proceed to PCI
  • Apply trial data and clinical guidelines on the use of antiplatelet therapy in patients undergoing revascularisation to a surrogate patient case
Register now Log in

Module

Title

Duration

Speakers

1 Guideline updates: A brief review of changes to the ESC 2020 guideline updates in NSTE-ACS in both the pre-intervention and post-PCI setting. Dominick Angiolillo (Jacksonville, USA) Rob Storey (University of Sheffield, UK) Roxana Mehran (New York, NY, USA) Gilles Montalescot (Paris, France)
2 Overview of clinical trials for patients undergoing intervention:
 a. PLATO
 b. TRITON-TIMI 38 
c. ACCOAST
 d. SCAAR
 e. ISAR-REACT 5 Dominick Angiolillo (Jacksonville, USA) Rob Storey (University of Sheffield, UK) Roxana Mehran (New York, NY, USA) Gilles Montalescot (Paris, France)
3 Deep dive into trial design: This session is designed to take a subjective view of the most recent changes in the ESC guidelines and to assess the trials and their design Dominick Angiolillo (Jacksonville, USA) Rob Storey (University of Sheffield, UK) Roxana Mehran (New York, NY, USA) Gilles Montalescot (Paris, France)
4 Example patient case: Patient of unknown coronary anatomy presenting for PCI. Dominick Angiolillo (Jacksonville, USA) Rob Storey (University of Sheffield, UK) Roxana Mehran (New York, NY, USA) Gilles Montalescot (Paris, France)
5 Audience Q&A Dominick Angiolillo (Jacksonville, USA) Rob Storey (University of Sheffield, UK) Roxana Mehran (New York, NY, USA) Gilles Montalescot (Paris, France)
1.

Guideline updates: A brief review of changes to the ESC 2020 guideline updates in NSTE-ACS in both the pre-intervention and post-PCI setting.

Duration:

Speakers: Dominick Angiolillo (Jacksonville, USA) Rob Storey (University of Sheffield, UK) Roxana Mehran (New York, NY, USA) Gilles Montalescot (Paris, France)

2.

Overview of clinical trials for patients undergoing intervention:
 a. PLATO
 b. TRITON-TIMI 38 
c. ACCOAST
 d. SCAAR
 e. ISAR-REACT 5

Duration:

Speakers: Dominick Angiolillo (Jacksonville, USA) Rob Storey (University of Sheffield, UK) Roxana Mehran (New York, NY, USA) Gilles Montalescot (Paris, France)

3.

Deep dive into trial design: This session is designed to take a subjective view of the most recent changes in the ESC guidelines and to assess the trials and their design

Duration:

Speakers: Dominick Angiolillo (Jacksonville, USA) Rob Storey (University of Sheffield, UK) Roxana Mehran (New York, NY, USA) Gilles Montalescot (Paris, France)

Speaker

Dominick Angiolillo

University of Florida College of Medicine-Jacksonville, Florida, US

Dr Dominick Angiolillo graduated from the Catholic University of the Sacred Heart Medical School in Rome, Italy and pursued training in interventional cardiology at the Complutense University of Madrid in Spain and received his Ph.D. in cellular and molecular cardiology. 

View full profile

Roxana Mehran

Mount Sinai Hospital, New York, NY, US

Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, FSCAI is Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine.

View full profile

Gilles Montalescot

Centre Hospitalier Universitaire Pitié-Salpêtrière

Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France

View full profile

Rob Storey

Department of Cardiovascular Science, University of Sheffield, Sheffield, UK

Prof. Storey is Academic Director and an honorary Consultant Cardiologist for the Cardiology and Cardiothoracic Surgery Directorate, Sheffield Teaching Hospitals NHS Foundation Trust.

View full profile

The programme ‘P2Y12 Receptor Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: An Assessment of Current Evidence’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

 

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

 

AVAILABLE CREDIT

1.00 European Board for Accreditation in Cardiology (EBAC)

Related Courses

TIO 2020 – CHIP Live Cases
  • 1.00 EBAC

Learning objectives

  • Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
  • Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
  • Assess the merits of adopting emerging technologies within their practice
  • Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
  • Interact with opinion leaders in their profession
See more
TIO 2020 – Focus on Calcified Lesions
  • 1.00 EBAC

Learning objectives

  • Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
  • Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
  • Assess the merits of adopting emerging technologies within their practice
  • Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
  • Interact with opinion leaders in their profession
See more
TIO 2020 – Technologies and Controversies
  • 1.00 EBAC

Learning objectives

  • Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
  • Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
  • Assess the merits of adopting emerging technologies within their practice
  • Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
  • Interact with opinion leaders in their profession
See more
TIO 2020 – Trials
  • 1.00 EBAC

Learning objectives

  • Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
  • Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
  • Assess the merits of adopting emerging technologies within their practice
  • Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
  • Interact with opinion leaders in their profession
See more
TIO 2020 – Live TAVI Cases
  • 1.00 EBAC

Learning objectives

  • Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
  • Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
  • Assess the merits of adopting emerging technologies within their practice
  • Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
  • Interact with opinion leaders in their profession
See more
TIO 2020 – CTO Live Cases
  • 1.00 EBAC

Learning objectives

  • Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
  • Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
  • Assess the merits of adopting emerging technologies within their practice
  • Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
  • Interact with opinion leaders in their profession
See more
TIO 2020 – Focus on CTO
  • 1.00 EBAC

Learning objectives

  • Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
  • Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
  • Assess the merits of adopting emerging technologies within their practice
  • Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
  • Interact with opinion leaders in their profession
See more